George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
https://www.medica-tradefair.com/vis/v1/en/exhibitors/medcom2022.2705520?oid=80396&lang=2
click on show co-exhibitors
https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-enhertu
The U.S. Department of Health and Human Services has just spent $290 million on Nplate a drug to treat radiation sickness.
HHS supports development of diagnostics, vaccines and treatments to respond to potential health impacts of such threats.
However Chris Meekins, former deputy assistant secretary for preparedness and response at HHS said,Nplate would not be the ideal medication to use for a widespread nuclear event, he added.
The drug needs to be used within 24 hours of exposure, he said, though the Federal Emergency Management Agency, or FEMA, recommends that people stay indoors for at least 24 hours after a nuclear blast.
“We need products that can be used longer,” he said.
https://www.nbcnews.com/health/health-news/us-purchase-radiation-sickness-drug-nplate-no-cause-alarm-rcna51252
https://magiceden.io/item-details/C3hadAwavN6uCwBWH7oE4NCKwJM3K1FoZmyi3R6myp7c
Current Price 25 sol
From the grant side i can`t see how we would not qualify for an orphan-drug-designation from the fda.
Not sure if you apply for it or it is given once ind submitted.